UTHR$595.940.89%-5.38
United Therapeutics Corp (UTHR)
Date: 2026-11-04 16:00O: 583.63H: 602.40L: 578.28C: 596.11Vol: 317.9k
United Therapeutics Corp stock is traded at $595.94, with a volume of 349,014. It is down -0.89% in the last 24 hours and up +10.01% over the past month. United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
Previous Close:
$601.32
Open:
$583.63
24h Volume:
349,014
Relative Volume:
0.65
Market Cap:
$25.56B
Revenue:
$3.17B
Net Income/Loss:
$1.29B
P/E Ratio:
21.99
EPS:
$27.09
Net Cash Flow:
$1.01B
1W Performance:
+1.61%
1M Performance:
+10.01%
6M Performance:
+2.53%
1Y Performance:
+36.27%
1-Day Range:
$578.28$602.40
1-Week Range:
$589.62$609.99
52-Week Range:
$430.02$609.99
United Therapeutics Corp Stock (UTHR) Company Profile
Name
United Therapeutics CorpSector
HealthcarePhone
(301) 608-9292Address
1000 SPRING ST, SILVER SPRING, MD, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
United Therapeutics Corp Stock (UTHR) Financials Data
United Therapeutics Corp Stock (UTHR) Insider Trading
- ROTHBLATT MARTINE ANov 02 '26Chairperson & CEO
- Transaction
- Sale
- Cost
- $596.22
- #Shares
- 9,500
- Value ($)
- 5,664,136
- #Shares Total
- 324,443
- ROTHBLATT MARTINE ANov 02 '26Chairperson & CEO
- Transaction
- Option Exercise
- Cost
- $117.76
- #Shares
- 9,500
- Value ($)
- 1,118,720
- #Shares Total
- 333,943
- MARTINE ROTHBLATTNov 02 '26Director
- Transaction
- Proposed Sale
- Cost
- $598.72
- #Shares
- 119,410
- Value ($)
- 71,493,155
- #Shares Total
- 0
- ROTHBLATT MARTINE AOct 30 '26Chairperson & CEO
- Transaction
- Option Exercise
- Cost
- $117.76
- #Shares
- 9,500
- Value ($)
- 1,118,720
- #Shares Total
- 333,943
- ROTHBLATT MARTINE AOct 30 '26Chairperson & CEO
- Transaction
- Sale
- Cost
- $600.09
- #Shares
- 9,500
- Value ($)
- 5,700,856
- #Shares Total
- 324,443
- ROTHBLATT MARTINE AOct 29 '26Chairperson & CEO
- Transaction
- Sale
- Cost
- $594.78
- #Shares
- 9,500
- Value ($)
- 5,650,415
- #Shares Total
- 324,443
- ROTHBLATT MARTINE AOct 29 '26Chairperson & CEO
- Transaction
- Option Exercise
- Cost
- $117.76
- #Shares
- 9,500
- Value ($)
- 1,118,720
- #Shares Total
- 333,943
- ROTHBLATT MARTINE AOct 28 '26Chairperson & CEO
- Transaction
- Option Exercise
- Cost
- $117.76
- #Shares
- 9,500
- Value ($)
- 1,118,720
- #Shares Total
- 333,943
- ROTHBLATT MARTINE AOct 28 '26Chairperson & CEO
- Transaction
- Sale
- Cost
- $585.49
- #Shares
- 9,500
- Value ($)
- 5,562,190
- #Shares Total
- 324,443
- ROTHBLATT MARTINE AOct 27 '26Chairperson & CEO
- Transaction
- Sale
- Cost
- $587.73
- #Shares
- 9,500
- Value ($)
- 5,583,418
- #Shares Total
- 324,443
